Literature DB >> 8519426

The effects of ventral tegmental administration of GABAA, GABAB and NMDA receptor agonists on medial forebrain bundle self-stimulation.

M L Willick1, L Kokkinidis.   

Abstract

Using a conditioned discrimination ICSS paradigm, rate-current intensity functions were determined for both reward- and nonreward-associated responding for electrical self-stimulation of the MFB following intra-VTA infusion of baclofen, muscimol and N-methyl-D,L-aspartate (NMDLA). A low dose (0.064 microgram/0.5 microliter) of the GABAB receptor agonist, baclofen, microinjected into the VTA, ipsilateral to the lateral hypothalamic stimulating electrode, resulted in a rightward shift of the ICSS curve without significantly influencing either maximal rates of operant responding for electrical brain stimulation or nonreinforced performance levels. Increases in MFB current thresholds were also evident after infusion of higher doses of baclofen (0.128, 0.26 and 0.52 microgram) into the ventral tegmentum. Intra-VTA administration of the GABAA receptor agonist, muscimol (0.006, 0.012, 0.025 and 0.05 microgram) and NMDA receptor activation by NMDLA (0.5, 1, 2 and 5 micrograms) did not affect reward thresholds; however, the low dose of muscimol and the high dose of NMDLA elicited behavioral activation resulting in reward-unrelated performance effects. These results implicate the specific involvement of the GABAB receptor in the reward neurocircuitry of the VTA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519426     DOI: 10.1016/0166-4328(94)00181-e

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  18 in total

Review 1.  Pregnane xenobiotic receptors and membrane progestin receptors: role in neurosteroid-mediated motivated behaviours.

Authors:  C A Frye; C J Koonce; A A Walf
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

Review 2.  3alpha-hydroxy-5alpha-pregnan-20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors.

Authors:  C A Frye; M E Rhodes; S M Petralia; A A Walf; K Sumida; K L Edinger
Journal:  Neuroscience       Date:  2005-12-01       Impact factor: 3.590

3.  Effects of manipulating progesterone and NMDA receptors in the ventral tegmental area for lordosis of hamsters and rats.

Authors:  Cheryl A Frye; Jennifer Marrone; Alicia Walf
Journal:  Psychopharmacology (Berl)       Date:  2008-06-29       Impact factor: 4.530

4.  Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABAA and GABAB receptor-mediated synaptic input.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

5.  Nucleus Accumbens Subnuclei Regulate Motivated Behavior via Direct Inhibition and Disinhibition of VTA Dopamine Subpopulations.

Authors:  Hongbin Yang; Johannes W de Jong; YeEun Tak; James Peck; Helen S Bateup; Stephan Lammel
Journal:  Neuron       Date:  2018-01-04       Impact factor: 17.173

Review 6.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

7.  Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.

Authors:  A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

Review 8.  Membrane actions of progestins at dopamine type 1-like and GABAA receptors involve downstream signal transduction pathways.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Steroids       Date:  2008-02-08       Impact factor: 2.668

9.  Unconditional hyperactivity and transient reinforcing effects of NMDA administration into the ventral tegmental area in rats.

Authors:  Satoshi Ikemoto
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

Review 10.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.